Shares Investor Evening (Manchester)
Macdonald Manchester Hotel
Thursday, October 10, 2019 - 06:00 PM
Until: Thursday, October 10, 2019 - 09:30 PM
(Adjusted for timezone: Europe/London)
Categories
The Shares and AJ Bell Media evening event in Manchester is an opportunity for senior board directors from fast growing listed PLCs to make a presentation about their company and update existing & potential investors on their business plans for 2019.
During the event and afterwards over drinks, investors will have the chance to discover new investment opportunities and get to know the companies better by talking one on one with the company directors
Companies presenting:
Belvoir Lettings - (BLV) - Belvoir Lettings is uniquely positioned within the property sector, benefiting from the agility of a franchise business model compared with the larger corporate players, whilst providing our networks with the Central Office systems and support, not available to the smaller independent agents
Mercia Technologies - (MERC) - Mercia is a national investment group focused on the funding and scaling of innovative technology businesses with high growth potential from the UK regions. Mercia benefits from 19 university partnerships and offices across the Midlands, the North of England and Scotland providing it with access to high quality, regional deal flow.
ReNeuron Group - (RENE) - ReNeuron Group is a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
SkinBio Therapeutics - (SBTX) - SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.The business strategy is to partner and outlicense its programmes at proof of concept.
VolitionRx – (VNRX) - VolitionRx is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Who Should Attend
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Evening timings
18.00 Registration and coffee
18.30 Presentations
Dorian Gonsalves, CEO - Belvoir Lettings
Martin Glanfield, CFO - Mercia Technologies (MERC)
Dr. Mark Payton, CEO - Mercia Technologies (MERC)
Michael Hunt, CFO - ReNeuron Group (RENE)
Cameron Reynolds, President & CEO - VolitionRx
SkinBioTherapeutics (SBTX)
20.30 Drinks reception and canapés
21.30 Close
During the event and afterwards over drinks, investors will have the chance to discover new investment opportunities and get to know the companies better by talking one on one with the company directors
Companies presenting:
Belvoir Lettings - (BLV) - Belvoir Lettings is uniquely positioned within the property sector, benefiting from the agility of a franchise business model compared with the larger corporate players, whilst providing our networks with the Central Office systems and support, not available to the smaller independent agents
Mercia Technologies - (MERC) - Mercia is a national investment group focused on the funding and scaling of innovative technology businesses with high growth potential from the UK regions. Mercia benefits from 19 university partnerships and offices across the Midlands, the North of England and Scotland providing it with access to high quality, regional deal flow.
ReNeuron Group - (RENE) - ReNeuron Group is a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
SkinBio Therapeutics - (SBTX) - SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.The business strategy is to partner and outlicense its programmes at proof of concept.
VolitionRx – (VNRX) - VolitionRx is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Who Should Attend
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Evening timings
18.00 Registration and coffee
18.30 Presentations
Dorian Gonsalves, CEO - Belvoir Lettings
Martin Glanfield, CFO - Mercia Technologies (MERC)
Dr. Mark Payton, CEO - Mercia Technologies (MERC)
Michael Hunt, CFO - ReNeuron Group (RENE)
Cameron Reynolds, President & CEO - VolitionRx
SkinBioTherapeutics (SBTX)
20.30 Drinks reception and canapés
21.30 Close